Skip to main content

Recent News & Research

EGFR Resister Logo
ResearchTreatments

Research Update: EGFR Resisters + LCRF

*June 2023* EGFR Resisters and LCRF are delighted to update supporters about the research made possible by their partnership! The EGFR Resisters Grant was awarded in 2021 to Yang Tian, PhD, Icahn School of Medicine at Mount Sinai. She joins us along with Hideo Watanabe, MD, PhD, who leads The Watanabe…
laurabbook@gmail.com
September 29, 2023
Clinical Lung Cancer Logo
ResearchTreatments

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab with and without Atezolizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

*May 2023* The emergence of immune checkpoint inhibitors has dramatically altered the treatment landscape of stage IV NSCLC with some patients now experiencing unprecedented long-term survival after PD-1/PD-L1 therapy. These individuals that benefit typically have smoking-induced lung tumors, while patients who have never smoked or have EGFR-driven NSCLC, generally possess…
laurabbook@gmail.com
September 28, 2023
targeted oncology
ResearchTreatments

Osimertinib and Chemotherapy Improves PFS in Advanced EGFRm NSCLC

*May 2023* Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.mpared to osimertinib alone and as such, can further delay treatment resistance and disease progression.” The combination of osimertinib (Tagrisso) with chemotherapy generated a statistically significant…
laurabbook@gmail.com
September 28, 2023
Clinical Cancer Research AACR
ResearchTreatments

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

*June 2023* Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small cell lung cancer harboring L747_A750>P and other uncommon ex19dels is not known. Design:The AACR GENIE database was interrogated to…
laurabbook@gmail.com
September 28, 2023
Nature Magazine
ResearchTreatments

Lung adenocarcinoma promotion by air pollutants

*April 2023* A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development1. Here we propose…
laurabbook@gmail.com
September 28, 2023